LPC
DYN icon

Lion Point Capital’s Dyne Therapeutics DYN Stock Holding History

Lion Point Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$400K Hold
18,000
– – 1.91% 20
2026
Q1 		$326K Hold
18,000
– – 1.95% 21
2025
Q4 		$352K Buy
+18,000
New +$341K 1.82% 25

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Lion Point Capital's DYN Position: Q2 2026 in Review

Lion Point Capital held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 18,000 shares worth $400K. The position accounts for 1.91% of the portfolio, ranked #20.

Lion Point Capital first reported a position in DYN in Q4 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Lion Point Capital held 18,000 shares of Dyne Therapeutics worth $400K as of Q2 2026.
  • Lion Point Capital left its Dyne Therapeutics share count unchanged in Q2 2026.
  • Dyne Therapeutics made up 1.91% of Lion Point Capital's portfolio in Q2 2026, its #20 holding.
  • Lion Point Capital first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.